Bank of New York Mellon Corp Acquires 30,382 Shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)

Bank of New York Mellon Corp increased its holdings in shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) by 33.1% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 122,051 shares of the company's stock after buying an additional 30,382 shares during the quarter. Bank of New York Mellon Corp owned 0.17% of Kiniksa Pharmaceuticals worth $2,414,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently bought and sold shares of KNSA. Braidwell LP boosted its holdings in Kiniksa Pharmaceuticals by 40.6% in the third quarter. Braidwell LP now owns 2,894,513 shares of the company's stock worth $72,334,000 after purchasing an additional 836,210 shares in the last quarter. Parkman Healthcare Partners LLC increased its holdings in shares of Kiniksa Pharmaceuticals by 16.7% during the 3rd quarter. Parkman Healthcare Partners LLC now owns 755,244 shares of the company's stock valued at $18,874,000 after acquiring an additional 108,102 shares during the last quarter. FMR LLC raised its stake in shares of Kiniksa Pharmaceuticals by 36,925.0% in the 3rd quarter. FMR LLC now owns 696,810 shares of the company's stock valued at $17,413,000 after acquiring an additional 694,928 shares in the last quarter. Jane Street Group LLC lifted its holdings in Kiniksa Pharmaceuticals by 1,064.4% in the 3rd quarter. Jane Street Group LLC now owns 345,092 shares of the company's stock worth $8,624,000 after purchasing an additional 315,456 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. boosted its position in Kiniksa Pharmaceuticals by 40.2% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 324,064 shares of the company's stock worth $8,098,000 after purchasing an additional 92,985 shares during the period. 53.95% of the stock is owned by institutional investors and hedge funds.

Remove Ads

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on the stock. Citigroup initiated coverage on shares of Kiniksa Pharmaceuticals in a report on Thursday, March 13th. They set a "buy" rating and a $40.00 price target for the company. Wedbush reaffirmed an "outperform" rating and issued a $34.00 target price on shares of Kiniksa Pharmaceuticals in a report on Tuesday, February 25th. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, Kiniksa Pharmaceuticals presently has an average rating of "Buy" and a consensus price target of $37.17.

Kiniksa Pharmaceuticals Stock Down 0.9 %

KNSA stock traded down $0.22 during midday trading on Tuesday, reaching $23.19. 363,017 shares of the company's stock traded hands, compared to its average volume of 406,763. Kiniksa Pharmaceuticals, Ltd. has a 1-year low of $16.56 and a 1-year high of $28.15. The company has a 50-day simple moving average of $20.40 and a two-hundred day simple moving average of $22.00. The company has a market cap of $1.68 billion, a price-to-earnings ratio of -165.63 and a beta of 0.48.

Kiniksa Pharmaceuticals (NASDAQ:KNSA - Get Free Report) last posted its quarterly earnings results on Tuesday, February 25th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by ($0.06). Kiniksa Pharmaceuticals had a negative net margin of 2.36% and a negative return on equity of 7.31%. The firm had revenue of $122.50 million during the quarter, compared to the consensus estimate of $123.42 million. During the same quarter in the prior year, the business earned $0.35 EPS. Kiniksa Pharmaceuticals's revenue was up 46.9% on a year-over-year basis. Equities research analysts forecast that Kiniksa Pharmaceuticals, Ltd. will post -0.55 EPS for the current year.

Insider Buying and Selling

In other news, CAO Michael R. Megna sold 9,051 shares of the stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $22.45, for a total value of $203,194.95. Following the transaction, the chief accounting officer now owns 26,528 shares of the company's stock, valued at $595,553.60. This represents a 25.44 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Mark Ragosa sold 36,372 shares of Kiniksa Pharmaceuticals stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $22.25, for a total value of $809,277.00. Following the sale, the chief financial officer now directly owns 22,958 shares of the company's stock, valued at approximately $510,815.50. This trade represents a 61.30 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 93,766 shares of company stock valued at $2,011,735 over the last ninety days. Insiders own 54.57% of the company's stock.

Kiniksa Pharmaceuticals Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.